Deep TechCrunch

[Deep TechCrunch @deeptechcrunch]

https://t.co/FsBmXmME1l

[Deep TechCrunch @deeptechcrunch]

6. Carbonaide announced a $1.9M seed in March 2023.

Their process binds CO2 into precast concrete using an automated system at atmospheric pressure. By reducing the quantity of required cement content and mineralizing CO2 into the concrete itself, they can reduce emissions 50%.

[Deep TechCrunch @deeptechcrunch]

6. Carbonaide announced a $1.9M seed in March 2023.

Their process binds CO2 into precast concrete using an automated system at atmospheric pressure. By reducing the quantity of required cement content and mineralizing CO2 into the concrete itself, they can reduce emissions 50%.

[Deep TechCrunch @deeptechcrunch]

Cement is responsible for 8% of global annual CO2 emissions.

This is almost double the impact of flying or shipping.

We cannot replace cement and demand is expected to increase as we build more infrastructure in both the developed and developing worlds.

[Deep TechCrunch @deeptechcrunch]

5. Carbon Re, spun out of Cambridge after raising a $4.8M seed in Nov 2022.

Theirs is an AI-driven approach that models the unique production environment of each plant and uses advanced machine learning to achieve previously outof-reach efficiency

https://t.co/o6NIbU0Oe6

[Deep TechCrunch @deeptechcrunch]

Find out more about Antiva Biosciences at: https://t.co/SjH3iuYoVV

[Deep TechCrunch @deeptechcrunch]

📢Fundraising announcement📢
Antiva Biosciences based in South San Francisco, USA has raised a $53M Series E funding round.

[Deep TechCrunch @deeptechcrunch]

Antiva has leveraged its development expertise to formulate a vaginal tablet of ABI-2280 that will enable self-administration at diagnosis and facilitate worldwide distribution.

[Deep TechCrunch @deeptechcrunch]

The Sensible rapid PCR platform is not currently cleared by the US FDA, nor does it have Emergency Use Authorization, and it is not currently for sale. The company is currently preparing to launch a Series A funding round.

[Deep TechCrunch @deeptechcrunch]

@Curative_Inc has spun off a new company, Sensible Diagnostics, to commercialize a 10-minute point-of-care PCR testing platform called the Sensible Platform.

[Deep TechCrunch @deeptechcrunch]

The platform will be launched with a respiratory test, but the firm said it was built to be extended to all types of infectious disease testing, such as sexually transmitted infections.